Bardy Diagnostics announced on 4/16/2019 that it has raised $35.5 million in Series B funding with a host of new investors. The funds will be used to further accelerate growth of its innovative P-wave focused cardiac monitoring platform and to support advanced development programs, including augmented intelligence and visualization technologies. BardyDx has several patent documents in the AI Biotech/Diagnostics sector, all directed to using artificial intelligence to either detect cardiac disorders or collect electrocardiograph data for future diagnostics. Its intellectual property may have played a role in allowing the 6-year-old company to attract the high level of investment.